Longitudinal Identification of Pre‐Lesional Tissue in Multiple Sclerosis With Advanced Diffusion MRI
Journal of Neuroimaging · 2025
DOI: 10.1111/jon.70022 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuroimaging, 2025. Verfasst von Maria Caranova und 7 weiteren Autor:innen. Beteiligte Einrichtung: Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Institute for Nuclear Sciences Applied to Health (ICNAS), University of …. Hauptthemen laut MEDLINE: Diffusion Magnetic Resonance Imaging, White Matter, Multiple Sclerosis, Relapsing-Remitting, Brain. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Fundação para a Ciência e Tecnologia.
Abstract (Originalsprache)
Background and Purpose Structural MRI (sMRI) is used in monitoring multiple sclerosis (MS) but lacks sensitivity in detecting clinically relevant damage to normal‐appearing white matter (NAWM), that is, pre‐lesional tissue, and specificity for identifying the underlying substrate of injury. In this longitudinal study, we identified pre‐lesional tissue in MS patients and investigated its microstructure by modeling diffusion‐weighted imaging (DWI) data using diffusion tensor imaging and neurite orientation dispersion and density imaging (NODDI).
Methods
We enrolled 18 patients with relapsing‐remitting MS (10 females, 31.92 ± 8.09 years, disease duration 0.91 ± 1.81 years) and 18 healthy controls (10 females, 31.89 ± 8.15 years). Participants underwent two sMRI and DWI sessions (baseline and follow‐up) with the same protocols. Average apparent diffusion coefficient (ADC), fractional anisotropy (FA), orientation dispersion index (ODI), and neurite density index (NDI) were estimated in data‐driven regions of interest: nonpersistent lesional tissue (lesional tissue at baseline, resolved at follow‐up), lesions that only existed at follow‐up (pre‐lesional tissue at baseline, lesions at follow‐up), persistent lesional tissue (lesions at baseline and follow‐up), and NAWM.
Results
Compared to NAWM, pre‐lesional tissue showed lower ODI, and resolved lesional tissue showed higher FA and ADC and lower ODI and NDI. Over time, persistent lesional tissue showed a decrease in FA and ODI and an increase in NDI. Compared to nonpersistent lesional tissue, persistent lesional tissue showed higher ADC and lower NDI.
Conclusions
DWI and, more particularly, NODDI, can reveal the unique microstructure of persistent, resolved, and pre‐lesional tissue in MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, Coimbra, Portugal.
- Neuroradiology Functional Unit, Imaging Service, Coimbra Local Health Unit, Coimbra, Portugal.
- Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
- Neurology Department, Coimbra Hospital and University Centre, Coimbra, Portugal.
- Champalimaud Research, Champalimaud Foundation, Lisbon, Portugal.
ORCID-Profile: Maria Caranova, Miguel Castelo-Branco
Förderung
- Fundação para a Ciência e Tecnologia
Zitieren
APA
Caranova, M., Soares, J. F., Pereira, D. J., Lima, A. C., Sousa, L., Batista, S., Castelo-Branco, M., & Duarte, J. V. (2025). Longitudinal Identification of Pre‐Lesional Tissue in Multiple Sclerosis With Advanced Diffusion MRI. Journal of Neuroimaging. https://doi.org/10.1111/jon.70022
Vancouver
Caranova M, Soares JF, Pereira DJ, Lima AC, Sousa L, Batista S, et al. Longitudinal Identification of Pre‐Lesional Tissue in Multiple Sclerosis With Advanced Diffusion MRI. Journal of Neuroimaging. 2025. doi:10.1111/jon.70022
BibTeX
@article{Caranova2025,
author = {Caranova, Maria and Soares, Júlia F and Pereira, Daniela Jardim and Lima, Ana Cláudia and Sousa, Lívia and Batista, Sónia and Castelo-Branco, Miguel and Duarte, João V},
title = {Longitudinal Identification of Pre‐Lesional Tissue in Multiple Sclerosis With Advanced Diffusion MRI},
journal = {Journal of Neuroimaging},
year = {2025},
doi = {10.1111/jon.70022}
}
EUVIMED